Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2020, with a filing date of January 13, 2020. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Transaction Type |
|---|---|---|---|---|
| January 9, 2020 | Ordinary Shares (25p each) | £17.9031 | 1,100 shares | Acquisition via Dividend Re-investment |
Note: The total volume of 1,100 shares is the aggregate of six individual transactions reported in the filing (9, 4, 1, 27, 663, and 400 shares).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine compliance disclosures for insider share acquisitions resulting from dividend re-investment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity transactions executed on the London Stock Exchange.
Key Facts for Investor Verification
- Transaction Nature: All reported share acquisitions were executed through the re-investment of dividends paid on January 9, 2020, rather than open market purchases.
- Participants: Transactions involved senior executives including the SVP of Global Ethics & Compliance, SVP of Global Communications, the Company Secretary, and their associated persons.
- Share Price: The acquisition price was uniform across all transactions at £17.9031 per share.
- Financial Data: This filing does not provide any data regarding GSK's overall financial performance, revenue, or earnings for the period.